SCHEMBL3757775

SCHEMBL3757775

O=C(NCCN1CCCC1)C(=O)Nc1cc[c]cc1

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
POLB P06746 1/20 0.55
CNR1 P21554 1/20 0.53
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
LMNA P02545 3/20 0.48
SMN1; SMN2 Q16637 4/20 0.47
GAA P10253 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ALDH1A1 P00352 2/20 0.46
EPHX2 P34913 1/20 0.46
HTT P42858 1/20 0.46
MAPT P10636 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4573277 0.87 MEN1 (0.72) MEN1KMT2APOLBCNR1LMNA
SCHEMBL3030023 0.78 ALDH1A1 (0.67) MEN1KMT2APOLBCYP2C9L3MBTL1
SCHEMBL1355051 0.78 ALDH1A1 (0.70) MEN1KMT2APOLBLMNASMN1; SMN2
SCHEMBL3041654 0.77 CYP1A2 (0.69) MEN1KMT2APOLBCYP2C9L3MBTL1
SCHEMBL6278367 0.77 ALDH1A1 (0.73) MEN1KMT2APOLBLMNAALDH1A1
SCHEMBL4573096 0.75 TP53 (0.49) MEN1KMT2APOLBCYP2C19LMNA
SCHEMBL3761624 0.75 SMN1; SMN2 (0.72) MEN1KMT2APOLBCNR1LMNA
SCHEMBL2184005 0.75 APAF1 (0.43) MEN1KMT2APOLBCNR1SMN1; SMN2
SCHEMBL1355565 0.74 KDM4E (0.67) MEN1KMT2APOLBLMNAGAA
SCHEMBL2181725 0.73 APAF1 (0.46) MEN1KMT2APOLBSMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA MEN1 2762/4885KMT2A 2175/4885POLB 2137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.